The recent TRIMCI study, conducted by different hospitals and scientific departments, indicate that treatment with triflusal in patients with amnestic mild cognitive impairment (CALP) can delay the progression of this disease to Alzheimer’s dementia.
Numerous epidemiological studies point to the potentially beneficial anti-inflammatory drugs in Alzheimer’s disease. However, so far the results of all clinical trials conducted with these drugs in patients with Alzheimer’s disease have been disappointing. Previous studies have demonstrated that triflusal, a drug used for platelet aggregation in laprevención of myocardial infarction and stroke is also a potent anti-inflammatory central nervous system.
Therefore, we conducted a clinical trial, the study TRIMCI to study the possible efficacy of triflusal to delay cognitive and functional deterioration and the onset of Alzheimer’s dementia in patients with emerging symptoms of memory loss. TRIMCI The study participants were randomized to receive Triflusal
(900 mg / day) or placebo for 18 months. A recruitment rate much slower than expected led to the premature termination of the trial after a mean follow up of patients randomized
13 months. During this time, 41 participants developed a picture of dementia, representing a conversion rate of 15% annually. In most cases, the cause of dementia was Alzheimer’s disease.
The DCLA represents, in many cases, a transition state between the cognitive changes of normal aging and early stage Alzheimer’s disease (AD). That is why scientists stress the importance of the clinical entity of CALP for the prevention of AD.
Previous research shows that between 10-15% of individuals with CALP progress annually to an Alzheimer type dementia compared with 1-2% of the general population, and age 6 that percentage reaches 80%. Therefore, the DCLS is a critical time to implement early therapeutic intervention in Alzheimer’s disease.
The results support the benefits of triflusal were obtained through a collaborative trial was conducted in Spain and Portugal, and in the same, involving 257 individuals over 60 years from 29 centers that met criteria for impairment amnestic mild cognitive (CALP), a subtype of DCL that in many cases represents the prelude to an Alzheimer’s dementia. During an average of 13 months patients received 900mg daily of triflusal, noting the relative risk reduction of progression to Alzheimer-type dementia was 52%.
The main finding in this study was that the probability of progression to Alzheimer’s dementia was significantly lower among participants who received Triflusal than among those who received placebo (hazard ratio (95% CI) 2.10 (1,10-4,01 ), P = 0.024).
“Although the trial was interrupted TRIMCI prematurely and consequently the results should be interpreted with caution, the beneficial effect of Triflusal detected in this study is an encouraging finding. Further studies are now needed confirmatory Triflusal potential beneficial effect in patients with CALP, “said Dr. Teresa Gómez Isla, a neurologist at the Hospital San Pablo de Barcelona and prestige nationally and internationally, who presented the results of TRIMCI study the X International Conference on Alzheimer’s.
Triflusal, known in the market as an effective alternative for patients who are intolerant of aspirin and suffer serious vascular events, now postulated as a treatment that could also benefit patients who are in the earliest stages of disease of.
Founded in 1838, Grupo Uriach is one of the oldest pharmaceutical companies in Spain. He has developed innovative drugs that have contributed to improving the health of people worldwide, and has been present in many countries.